Patents Assigned to Sun Pharma Advanced Research Company Ltd.
  • Patent number: 11951106
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 9, 2024
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11931359
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: March 19, 2024
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Publication number: 20240066014
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 29, 2024
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
  • Patent number: 11813252
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: November 14, 2023
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
  • Patent number: 11583522
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: February 21, 2023
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
  • Patent number: 11465990
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 11, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
  • Publication number: 20220273632
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 1, 2022
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
  • Patent number: 11304898
    Abstract: A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 19, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Wen Wee Ma, Alex Adjei, Lynne Bui, Ronald Harning, Ajay Khopade, Subhas Bhowmick, Natarajan Arulsudar, Narendra Lakkad
  • Patent number: 11241443
    Abstract: The present invention relates to an ophthalmic solution comprising (i) bimatoprost or its pharmaceutically acceptable salt in an amount ranging from about 0.005% to 0.015% weight by volume; (ii) a biguanide compound in an amount ranging from about 0.003% to 0.05% weight by volume; (iii) an acylated amino acid in an amount ranging from about 0.01% to 0.1% weight by volume; (iv) pharmaceutically acceptable excipients and (v) purified water.
    Type: Grant
    Filed: April 7, 2018
    Date of Patent: February 8, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11225480
    Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 18, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V. S. N. Murty Kadiyala, Sairam V V M Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
  • Publication number: 20210137921
    Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 13, 2021
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra DHARMADIKARI, Yashoraj R. ZALA, Ashwini GADKARI
  • Publication number: 20210015805
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
  • Patent number: 10849887
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: December 1, 2020
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
  • Publication number: 20200000803
    Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Applicant: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nitin Bhalachandra Dharmadikari, Yashoraj Zala, Ashwini Gadkari
  • Patent number: 10512608
    Abstract: The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting agent and (iii) a non-aqueous liquid vehicle, wherein the composition is free of water. The present invention also relates to a method of treating acne, rosacea, impetigo or a skin disease caused by a bacteria, by topical application of a nanoparticulate topical composition comprising nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: December 24, 2019
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Madhusudhan Bommagani, Subhas Balaram Bhowmick, Prashant Kane, Vaibhav Dubey
  • Patent number: 10413543
    Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 17, 2019
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadikari, Yashoraj Zala, Ashwini Gadkari
  • Publication number: 20190275017
    Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 12, 2019
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
  • Patent number: 10226428
    Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a swellable composition located in an immediate vicinity of one or more preselected surfaces. The coating comprises a defect wherein said defect is not a passageway through the preselected portion of the coating and operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 12, 2019
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
  • Patent number: 10213387
    Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 26, 2019
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
  • Patent number: 10172852
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: January 8, 2019
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder